NRD
MRVI icon

Nebula Research & Development’s Maravai LifeSciences MRVI Stock Holding History

Nebula Research & Development’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-35,309
Closed -$231K – 903
2023
Q4 		$231K Buy
+35,309
New +$228K 0.07% 513

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nebula Research & Development's MRVI Position: Q1 2024 in Review

Nebula Research & Development sold out of Maravai LifeSciences (MRVI) in Q1 2024, closing a stake of 35,309 shares — an estimated $231K sold.

Nebula Research & Development first reported a position in MRVI in Q4 2023 and held it in 1 quarter. The position peaked at $231K in Q4 2023. 210 funds tracked by Wall St. Rank hold MRVI as of Q1 2024.

  • Nebula Research & Development reported no remaining Maravai LifeSciences position as of Q1 2024 after selling out during the quarter.
  • Nebula Research & Development sold 35,309 Maravai LifeSciences shares in Q1 2024, an estimated $231K.
  • Nebula Research & Development first reported a position in Maravai LifeSciences in Q4 2023 and held it in 1 quarter.
  • Nebula Research & Development's Maravai LifeSciences position peaked at $231K in Q4 2023.
  • 210 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2024.

Based on Nebula Research & Development's 13F filing for Q1 2024, filed 15 May 2024.